tetano
Editor, Senior Moderator
Nat Microbiol
. 2023 May;8(5):771-786.
doi: 10.1038/s41564-023-01356-4. Epub 2023 May 4. Therapeutics for COVID-19
Sima S Toussi[SUP] 1 [/SUP], Jennifer L Hammond[SUP] 2 [/SUP], Brian S Gerstenberger[SUP] 3 [/SUP], Annaliesa S Anderson[SUP] 4 [/SUP]
Affiliations
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019 (COVID-19) illness were available within a year of the pandemic being declared but there remained an urgent need for therapeutics to treat patients who were not vaccinated, were immunocompromised or whose vaccine immunity had waned. Initial results for investigational therapies were mixed. AT-527, a repurposed nucleoside inhibitor for hepatitis C virus, enabled viral load reduction in a hospitalized cohort but did not reduce viral load in outpatients. The nucleoside inhibitor molnupiravir prevented death but failed to prevent hospitalization. Nirmatrelvir, an inhibitor of the main protease (Mpro), co-dosed with the pharmacokinetic booster ritonavir, reduced hospitalization and death. Nirmatrelvir-ritonavir and molnupiravir received an Emergency Use Authorization in the United States at the end of 2021. Immunomodulatory drugs such as baricitinib, tocilizumab and corticosteroid, which target host-driven COVID-19 symptoms, are also in use. We highlight the development of COVID-19 therapies and the challenges that remain for anticoronavirals.
. 2023 May;8(5):771-786.
doi: 10.1038/s41564-023-01356-4. Epub 2023 May 4. Therapeutics for COVID-19
Sima S Toussi[SUP] 1 [/SUP], Jennifer L Hammond[SUP] 2 [/SUP], Brian S Gerstenberger[SUP] 3 [/SUP], Annaliesa S Anderson[SUP] 4 [/SUP]
Affiliations
- PMID: 37142688
- DOI: 10.1038/s41564-023-01356-4
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019 (COVID-19) illness were available within a year of the pandemic being declared but there remained an urgent need for therapeutics to treat patients who were not vaccinated, were immunocompromised or whose vaccine immunity had waned. Initial results for investigational therapies were mixed. AT-527, a repurposed nucleoside inhibitor for hepatitis C virus, enabled viral load reduction in a hospitalized cohort but did not reduce viral load in outpatients. The nucleoside inhibitor molnupiravir prevented death but failed to prevent hospitalization. Nirmatrelvir, an inhibitor of the main protease (Mpro), co-dosed with the pharmacokinetic booster ritonavir, reduced hospitalization and death. Nirmatrelvir-ritonavir and molnupiravir received an Emergency Use Authorization in the United States at the end of 2021. Immunomodulatory drugs such as baricitinib, tocilizumab and corticosteroid, which target host-driven COVID-19 symptoms, are also in use. We highlight the development of COVID-19 therapies and the challenges that remain for anticoronavirals.